ERBB2 and non-small cell lung carcinoma: The clinical impact of HER3 is also exacerbated by its co-expression with other EGFR family members, notably HER2 and EGFR, which is linked to a more aggressive NSCLC phenotype and therapeutic resistance (39, 41, 42).